The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...

Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

People taking Eli Lilly’s obesity ... director of the Comprehensive Weight Control Center at Weill Cornell Medicine. “Two drugs together can produce better weight loss,” said Aronne, who ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. Lilly ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk. The importance of biosimilars only continues to ...

Most deal activity in the obesity and weight-loss sector is dominated by international big pharma, as companies race to sustain and expand their drug pipelines. 1. Eli Lilly purchased Versanis for ...